Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?

被引:43
作者
Bosma, L. V. A. E. [1 ]
Kragt, J. J. [1 ]
Brieva, L. [2 ]
Khaleeli, Z. [3 ]
Montalban, X. [2 ]
Polman, C. H. [1 ]
Thompson, A. J. [3 ]
Tintore, M. [2 ]
Uitdehaag, B. M. J. [1 ,4 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands
[2] Hosp Univ Vall Hebron, Unitat Neuroimmunol Clin, Barcelona, Spain
[3] UCL, Dept Brain Repair & Rehabil, Inst Neurol, London, England
[4] Vrije Univ Amsterdam Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands
关键词
9-Hole Peg Test; multiple sclerosis; Multiple Sclerosis Functional Composite; outcome measurement; Paced Auditory Serial Addition Test; primary progressive; Timed 25-Foot Walk; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; INTERFERON BETA-1A; OUTCOME MEASURE; RELIABLE CHANGE; CLINICAL-TRIAL; MS; MULTICENTER; DISABILITY; NATALIZUMAB;
D O I
10.1177/1352458510370464
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
For the Timed 25-Foot Walk (T25FW) and 9-Hole Peg Test (9HPT), components of the Multiple Sclerosis Functional Composite (MSFC), cut-off points of 20% change have previously been defined as meaningful endpoints of functional decline. Recently, however, a 15% change of MSFC components was introduced. The objective of this study was to determine optimal cut-offs for all MSFC components to indicate clinical disease progression in a primary progressive (PP) multiple sclerosis (MS) population. T25FW, 9HPT and the Paced Auditory Serial Addition Test (PASAT) were performed in 161 patients with PPMS with a 2-year interval. Absolute and relative differences in test scores were calculated. For each cut-off point of relative change, proportions of patients who progressed (deterioration beyond cut-off value) and improved (improvement beyond cut-off value) were calculated. Further, we calculated the ratio of 'improved' versus 'progressed' patients. Line graphs were created indicating: percentage progressed patients, percentage improved patients, and ratio of improved versus progressed patients. The optimal cut-off was determined by searching the cutoff point with the lowest ratio of improved versus progressed patients, while at the same time capturing a substantial amount of progression. For both T25FW and 9HPT, the ratio between patients that improved and worsened clearly decreased between the cut-offs of 15% and 20%. For the PASAT, the ratio between patients improved and worsened was persistently poor. In conclusion, a cut-off of 20% for both T25FW and 9HPT has a better signal-to-noise ratio than lower values (e.g. 15%) and is therefore preferable for the assessment of disease progression. No satisfactory cut-off point for the PASAT could be determined.
引用
收藏
页码:862 / 867
页数:6
相关论文
共 25 条
[1]   Selective decline in information processing in subgroups of multiple sclerosis: An 8-year longitudinal study [J].
Bergendal, G. ;
Fredrikson, S. ;
Almkvist, O. .
EUROPEAN NEUROLOGY, 2007, 57 (04) :193-202
[2]   The search for responsive clinical endpoints in primary progressive multiple sclerosis [J].
Bosma, L. V. A. E. ;
Kragt, J. J. ;
Brieva, L. ;
Khaleeli, Z. ;
Montalban, X. ;
Polman, C. H. ;
Thompson, A. J. ;
Tintore, M. ;
Uitdehaag, B. M. J. .
MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (06) :715-720
[3]   Intrarater and interrater reliability of the MS functional composite outcome measure [J].
Cohen, JA ;
Fischer, JS ;
Bolibrush, DM ;
Jak, AJ ;
Kniker, JE ;
Mertz, LA ;
Skaramagas, TT ;
Cutter, GR .
NEUROLOGY, 2000, 54 (04) :802-806
[4]   Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial [J].
Cohen, JA ;
Cutter, GR ;
Fischer, JS ;
Goodman, AD ;
Heidenreich, FR ;
Jak, AJ ;
Kniker, JE ;
Kooijmans, MF ;
Lull, JM ;
Sandrock, AW ;
Simon, JH ;
Simonian, NA ;
Whitaker, JN .
ARCHIVES OF NEUROLOGY, 2001, 58 (06) :961-967
[5]   Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study [J].
Comi, G ;
Filippi, M ;
Barkhof, F ;
Durelli, L ;
Edan, G ;
Fernández, O ;
Hartung, HP ;
Seeldrayers, P ;
Sorensen, PS ;
Rovaris, M ;
Martinelli, V ;
Hommes, OR .
LANCET, 2001, 357 (9268) :1576-1582
[6]   European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis [J].
Comi, G ;
Filippi, M ;
Wolinsky, JS .
ANNALS OF NEUROLOGY, 2001, 49 (03) :290-297
[7]   Development of a multiple sclerosis functional composite as a clinical trial outcome measure [J].
Cutter, GR ;
Baier, ML ;
Rudick, RA ;
Cookfair, DL ;
Fischer, JS ;
Petkau, J ;
Syndulko, K ;
Weinshenker, BG ;
Antel, JP ;
Confavreux, C ;
Ellison, GW ;
Lublin, F ;
Miller, AE ;
Rao, SM ;
Reingold, S ;
Thompson, A ;
Willoughby, E .
BRAIN, 1999, 122 :871-882
[8]   Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test [J].
Drake, A. S. ;
Weinstock-Guttman, B. ;
Morrow, S. A. ;
Hojnacki, D. ;
Munschauer, F. E. ;
Benedict, R. H. B. .
MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (02) :228-237
[9]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[10]   Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].
Ebers, GC ;
Rice, G ;
Lesaux, J ;
Paty, D ;
Oger, J ;
Li, DKB ;
Beall, S ;
Devonshire, V ;
Hashimoto, S ;
Hooge, J ;
Kastrukoff, L ;
Krieger, C ;
Mezei, M ;
Seland, P ;
Vorobeychi, G ;
Morrison, W ;
Nelson, J ;
Freedman, MS ;
Chrisie, S ;
Nelson, R ;
Rabinovitch, H ;
Freedman, C ;
Hartung, HP ;
Rieckmann, P ;
Archelos, J ;
Jung, S ;
Weilbach, F ;
Flachenecke, P ;
Sauer, J ;
Hommes, O ;
Jongen, P ;
Brouwer, S ;
McLeod, J ;
Pollard, J ;
Ng, R ;
Sandberg-Wollheim, M ;
Källén, K ;
Nilsson, P ;
Ekberg, R ;
Lundgren, A ;
Jadbäck, G ;
Wikström, J ;
Multanen, J ;
Valjakka, M ;
Carton, H ;
Lissoir, F ;
Declerq, I ;
Vieren, M ;
Peeters, E ;
Dubois, B .
LANCET, 1998, 352 (9139) :1498-1504